Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) - Full Text View

Sponsor:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00080262

Purpose

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

Condition	Intervention	Phase
Breast Cancer Metastases	Drug: Ixabepilone	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Ixabepilone

U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Response rate as determined by the IRRC

Secondary Outcome Measures:

Time to progression, duration of response, overall survival

Estimated Enrollment:	125
Study Start Date:	February 2004

Arms	Assigned Interventions
1: Experimental	Drug: Ixabepilone Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
No more than 3 prior chemotherapy regimens in the metastatic setting
Must have at least one target lesion that is radiographically measurable
Good performance status
No history of or current brain or leptomeningeal disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00080262

Hide Study Locations

Locations

United States, California
Local Institution
La Verne, California, United States
United States, Connecticut
Local Institution
Meriden, Connecticut, United States
United States, Florida
Local Institution
Jacksonville, Florida, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Massachusetts
Local Institution
Boston, Massachusetts, United States
United States, New York
Local Institution
New York, New York, United States
United States, North Carolina
Local Institution
Charlotte, North Carolina, United States
Local Institution
Asheville, North Carolina, United States
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Local Institution
Providence, Rhode Island, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
Local Institution
Knoxville, Tennessee, United States
Local Institution
Jackson, Tennessee, United States
Local Institution
Chattanooga, Tennessee, United States
United States, Texas
Local Institution
Houston, Texas, United States
Local Institution
San Antonio, Texas, United States
United States, Utah
Local Institution
Salt Lake City, Utah, United States
Argentina
Local Institution
Santa Fe, Argentina
Local Institution
Buenos Aires, Argentina
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
France
Local Institution
Besancon Cedex, France
Local Institution
Bobigny, France
Local Institution
Vandoeuvre Les Nancy, France
Local Institution
Marseille Cedex 9, France
Local Institution
Dijon Cedex, France
Local Institution
Lyon, France
Local Institution
Clermont-Ferrand, France
Germany
Local Institution
Frankfurt Hoechst, Germany
Local Institution
Frankfurt, Germany
Mexico
Local Institution
Chihuahua, Mexico
Local Institution
Distrito Federal, Mexico
Local Institution
Distrito Federal, Mexico
Mexico, Yucatan
Local Institution
Merida, Yucatan, Mexico
Netherlands
Local Institution
Leiden, Netherlands
Local Institution
Amsterdam, Netherlands
Norway
Local Institution
Oslo, Norway
Local Institution
Trondheim, Norway
South Africa, Eastern Cape
Local Institution
Port Elizabeth, Eastern Cape, South Africa
South Africa, Free State
Local Institution
Fichardtpark, Free State, South Africa
South Africa, Gauteng
Local Institution
Pretoria, Gauteng, South Africa
South Africa, Kwa Zulu Natal
Local Institution
Overport, Kwa Zulu Natal, South Africa
South Africa, Western Cape
Local Institution
Panorama, Western Cape, South Africa
Sweden
Local Institution
Malmo, Sweden
Local Institution
Stockholm, Sweden
Local Institution
Lund, Sweden
Local Institution
Helsingborg, Sweden

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators

Study Director:

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CA163-081
Study First Received:	March 25, 2004
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00080262 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Metastatic Breast Cancer

Additional relevant MeSH terms:

Skin Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Epothilones
Mitosis Modulators
Breast Neoplasms
Antimitotic Agents
Pharmacologic Actions

Neoplasms
Neoplastic Processes
Neoplasms by Site
Pathologic Processes
Therapeutic Uses
Tubulin Modulators
Neoplasm Metastasis
Breast Diseases

ClinicalTrials.gov processed this record on November 27, 2009